Novo Nordisk: treatment recommended by EU authorities

(CercleFinance.com) - The group announces that Wegovy has been recommended by European regulatory authorities for a label update to reflect the reduction in heart failure symptoms and improvement in physical function.


Wegovy (semaglutide 2.4 mg) is the first obesity drug to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise function in people with obesity-related heart failure with preserved ejection fraction (pEHF).

The positive opinion is based on the results of the STEP HFpEF and STEP HFpEF-DM trials, which showed that Wegovy is an effective therapy compared with placebo for people with obesity-related HFpEF.

The Head of Development at Novo Nordisk said that Wegovy improves patients' health-related quality of life, enabling them to live a life with greater functionality to carry out daily activities.


Copyright (c) 2024 CercleFinance.com. All rights reserved.